Unlock stock picks and a broker-level newsfeed that powers Wall Street.

KOSDAQ - Delayed Quote KRW

HLB Therapeutics Co.,Ltd. (115450.KQ)

7,820.00
+30.00
+(0.39%)
At close: 3:30:30 PM GMT+9

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
NameTitlePayExercisedYear Born
Mr. Doug Jang Founder -- -- --

HLB Therapeutics Co.,Ltd.

Parkview Office Tower
22nd floor 248 Jeongjail-ro Bundang-gu
Seongnam
South Korea
82 3 1786 7800 https://hlbtherapeutics.co.kr
Sector: 
Healthcare
Industry: 
Biotechnology

Description

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.

Corporate Governance

HLB Therapeutics Co.,Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 14, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC

HLB Therapeutics Co.,Ltd. Earnings Date

Recent Events